140 related articles for article (PubMed ID: 9083710)
1. On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets.
Johannessen T; Kristensen P
Clin Ther; 1997; 19(1):73-81. PubMed ID: 9083710
[TBL] [Abstract][Full Text] [Related]
2. Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease.
Engzelius JM; Solhaug JH; Knapstad LJ; Kjaersgaard P
Scand J Gastroenterol; 1997 Jun; 32(6):513-8. PubMed ID: 9200279
[TBL] [Abstract][Full Text] [Related]
3. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.
Kahrilas PJ; Fennerty MB; Joelsson B
Am J Gastroenterol; 1999 Jan; 94(1):92-7. PubMed ID: 9934737
[TBL] [Abstract][Full Text] [Related]
4. Low-dose famotidine and ranitidine as single post-prandial doses: a three-period placebo-controlled comparative trial.
Reilly TG; Singh S; Cottrell J; Mann SG; Stauffer L; Walt RP
Aliment Pharmacol Ther; 1996 Oct; 10(5):749-55. PubMed ID: 8899083
[TBL] [Abstract][Full Text] [Related]
5. Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis.
Fiorucci S; Santucci L; Perrone E; Abbritti F; Morelli A
Scand J Gastroenterol; 1989 Aug; 24(6):671-7. PubMed ID: 2573143
[TBL] [Abstract][Full Text] [Related]
6. Gastroesophageal reflux and histamine2 antagonists.
Bell SG
Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
[No Abstract] [Full Text] [Related]
7. Comparison of once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study.
Dobrilla G; De Pretis G; Piazzi L; Boero A; Camarri E; Crespi M; Fontana G; Ideo G; Manenti F; Marenco G
Scand J Gastroenterol Suppl; 1987; 134():21-8. PubMed ID: 2889255
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity.
Netzer P; Brabetz-Höfliger A; Bründler R; Flogerzi B; Hüsler J; Halter F
Aliment Pharmacol Ther; 1998 Apr; 12(4):337-42. PubMed ID: 9690722
[TBL] [Abstract][Full Text] [Related]
9. Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Hamilton MI; Sercombe J; Pounder RE
Aliment Pharmacol Ther; 2001 Oct; 15(10):1579-83. PubMed ID: 11563997
[TBL] [Abstract][Full Text] [Related]
10. Onset of action of antisecretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease.
Pipkin GA; Mills JG
Scand J Gastroenterol Suppl; 1999; 230():3-8. PubMed ID: 10499455
[TBL] [Abstract][Full Text] [Related]
11. Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp IC
Hepatogastroenterology; 1992 Feb; 39 Suppl 1():24-6. PubMed ID: 1577391
[TBL] [Abstract][Full Text] [Related]
12. Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Grimley CE; West JM; Loft DE; Cottrell J; Mann SG; Stauffer L; Nwokolo CU
Aliment Pharmacol Ther; 1996 Oct; 10(5):743-7. PubMed ID: 8899082
[TBL] [Abstract][Full Text] [Related]
13. A controlled comparison of continuous ranitidine and intermittent famotidine infusions on gastric pH.
Bachmann K; Sullivan TJ; Jauregui L
J Clin Pharmacol; 1993 Dec; 33(12):1219-24. PubMed ID: 7907348
[TBL] [Abstract][Full Text] [Related]
14. Novel oral medication delivery system for famotidine.
Schwartz JI; Yeh KC; Berger ML; Tomasko L; Hoover ME; Ebel DL; Stauffer LA; Han R; Bjornsson TD
J Clin Pharmacol; 1995 Apr; 35(4):362-7. PubMed ID: 7650224
[TBL] [Abstract][Full Text] [Related]
15. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
Zhao F; Wang S; Liu L; Wang Y
Int J Clin Pharmacol Ther; 2016 Oct; 54(10):761-70. PubMed ID: 27443665
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Madani S; Kauffman R; Simpson P; Lehr VT; Lai ML; Sarniak A; Tolia V
J Clin Pharmacol; 2014 Feb; 54(2):201-5. PubMed ID: 24258773
[TBL] [Abstract][Full Text] [Related]
19. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.
Komazawa Y; Adachi K; Mihara T; Ono M; Kawamura A; Fujishiro H; Kinoshita Y
J Gastroenterol Hepatol; 2003 Jun; 18(6):678-82. PubMed ID: 12753150
[TBL] [Abstract][Full Text] [Related]
20. Ranitidine (Zantac) syrup versus Ranitidine effervescent tablets (Zantac) EFFERdose) in children: a single-center taste preference study.
Ameen VZ; Pobiner BF; Giguere GC; Carter EG
Paediatr Drugs; 2006; 8(4):265-70. PubMed ID: 16898856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
